IP Library › Granted Patent US 12,421,296
Granted Patent B2
US 12,421,296 · App. 18/591,918 · Granted Sep 23, 2025

Activin receptor type IIB variants and uses thereof

Inventors: Maureen O'Connor-McCourt (Montreal, CA); Vannakambadi K. Ganesh (Montreal, CA); Gilles Tremblay (Montreal, CA); Gauthier Schang (Montreal, CA)
Assignee: 35PHARMA Inc.
C07K14/71A61P9/12C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,421,296
App. No.
18/591,918
Granted
Sep 23, 2025
Kind
B2
Abstract

There are provided polypeptides that include an Activin receptor type IIB (ActRIIB) ectodomain (ECD) variant. In some embodiments, a polypeptide of the disclosure includes an ActRIIB-ECD variant fused to an Fc domain moiety. The disclosure also provides pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions associated with TGFβ superfamily ligand signaling, such as pulmonary hypertension, fibrosis, muscle weakness and atrophy, metabolic disorders and/or cardiometabolic disease, bone damage, and/or low red blood cell levels (such as anemia).

Claims (36)

1. A nucleic acid molecule encoding a polypeptide comprising:

(a) an Activin receptor type IIB (ActRIIB) ectodomain (ECD) variant comprising the amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO: 2, wherein the ActRIIB-ECD variant comprises a substitution F58Q relative to the human wild type ActRIIB-ECD of SEQ ID NO: 2;

(b) a peptide linker comprising at least 10 amino acids; and

(c) an immunoglobulin (Ig) Fc domain monomer.

2. The nucleic acid molecule of claim 1 , wherein the ActRIIB-ECD variant comprises the amino acid sequence that is at least 95% identical to SEQ ID NO: 9.

3. The nucleic acid molecule of claim 1 , wherein the ActRIIB-ECD variant further comprises GRGEA (SEQ ID NO: 23) at the N terminus.

4. The nucleic acid molecule of claim 1 , wherein the polypeptide comprises from N- to C-terminus: the ActRIIB-ECD variant-the peptide linker-the Ig Fc domain monomer.

5. The nucleic acid molecule of claim 1 , wherein the Ig Fc domain monomer is an IgG1, IgG2, IgG3 or IgG4 isotype.

6. The nucleic acid molecule of claim 1 , wherein the Ig Fc domain monomer is engineered to reduce aggregation or to modulate stability of a dimer of the polypeptide.

7. The nucleic acid molecule of claim 1 , wherein the Ig Fc domain monomer comprises the amino acid substitutions of M252Y, S254T, and T256E (YTE).

8. The nucleic acid molecule of claim 1 , wherein the Ig Fc domain monomer comprises the M252Y amino acid substitution.

9. The nucleic acid molecule of claim 1 , wherein the Ig Fc domain monomer comprises D at position 356 and L at position 358 (DL).

10. The nucleic acid molecule of claim 1 , wherein the Ig Fc domain monomer comprises E at position 356 and M at position 358 (EM).

11. The nucleic acid molecule of claim 1 , wherein the Ig Fc domain monomer further comprises lysine residue (K) at the C terminus.

12. The nucleic acid molecule of claim 1 , wherein the Ig Fc domain monomer comprises the amino acid sequence that is at least 85% identical to any one of SEQ ID NOs: 134-173 and 338.

13. The nucleic acid molecule of claim 1 , wherein the Ig Fc domain monomer is:

(a) an IgG1 isotype and comprises the amino acid sequence of SEQ ID NO: 135 or SEQ ID NO: 134; or

(b) an IgG2 isotype and comprises the amino acid sequence of SEQ ID NO: 157.

14. The nucleic acid molecule of claim 1 , wherein the peptide linker is between 10 and 40 amino acids in length.

15. The nucleic acid molecule of claim 1 , wherein the peptide linker is 10 amino acids in length, 14 amino acids in length, 19 amino acids in length, or 39 amino acids in length.

16. The nucleic acid molecule of claim 1 , wherein the peptide linker comprises the amino acid sequence of any one of SEQ ID NOs: 34, 54, or 59.

17. The nucleic acid molecule of claim 1 , wherein the polypeptide comprises the amino acid sequence that is at least 95% identical to any one selected from the group consisting of SEQ ID NOs: 220-223 and 253.

18. The nucleic acid molecule of claim 1 , wherein the polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 220-223 and 253.

19. The nucleic acid molecule of claim 1 , wherein the polypeptide further comprises an albumin-binding domain, a fibronectin domain, or a human serum albumin domain fused to the N- or C-terminus of the ActRIIB-ECD variant via a second linker.

20. The nucleic acid molecule of claim 1 , wherein the polypeptide further comprises a signal peptide of SEQ ID NO: 1 at the N-terminus of the ActRIIB-ECD variant.

21. The nucleic acid molecule of claim 1 , comprising the nucleic acid sequence that is at least 90%, 95%, 96%, 97%, 98%, or 99% identical to any sequence selected from the group consisting of SEQ ID NOs: 302-305 and 325.

22. A vector comprising the nucleic acid molecule of claim 1 .

23. The vector of claim 22 , wherein the vector is a plasmid.

24. A host cell comprising the vector of claim 22 .

25. The host cell of claim 24 , wherein the host cell is a eukaryotic cell or a bacterial cell.

26. The host cell of claim 25 , wherein the eukaryotic cell is selected from the group consisting of Chinese Hamster Ovary (CHO) cell, HeLa cell, Madin-Darby canine kidney (MDCK) cell, Human Embryonic Kidney (HEK) 293 cell, and W138 cell.

27. The host cell of claim 25 , wherein the bacterial cell is Escherichia coli.

28. A method of preparing a polypeptide encoded by the nucleic acid molecule of claim 1 comprising:

(a) providing a host cell comprising a vector comprising the nucleic acid molecule of claim 1 ;

(b) culturing the host cell under conditions allowing expression of the encoded polypeptide; and

(c) recovering the expressed polypeptide from the culture.

Assignments (5)
MERGER Recorded Aug 4, 2026
From: 1001508446 ONTARIO INC.
To: 35PHARMA INC.
Reel/Frame 075516/0305 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2026
From: 35PHARMA INC.
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED
Reel/Frame 075516/0532 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2024
From: O'CONNOR-MCCOURT, MAUREEN; TREMBLAY, GILLES; SCHANG, GAUTHIER
To: 35PHARMA INC.
Reel/Frame 067238/0195 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2024
From: GANESH, VANNAKAMBADI K.
To: IXM LABS INC.
Reel/Frame 067238/0213 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2024
From: IXM LABS INC.
To: 35PHARMA INC.
Reel/Frame 067238/0220 →
Continuity (6)
Division 18160787 · Jan 27, 2023
Provisional Application 63420999 · Oct 31, 2022
Provisional Application 63416852 · Oct 17, 2022
Provisional Application 63397773 · Aug 12, 2022
Provisional Application 63304478 · Jan 28, 2022
Related Publication 20240262886A1 · Aug 8, 2024
References Cited (143)
US 5693607A · Segarini et al. · 1997 [cited by applicant]
US 7612041B2 · Knopf et al. · 2009 [cited by applicant]
US 7709605B2 · Knopf et al. · 2010 [cited by applicant]
US 7842663B2 · Knopf et al. · 2010 [cited by applicant]
US 7951771B2 · Knopf et al. · 2011 [cited by applicant]
US 7988973B2 · Sherman · 2011 [cited by applicant]
US 8007809B2 · Sherman · 2011 [cited by applicant]
US 8058229B2 · Seehra et al. · 2011 [cited by applicant]
US 8216997B2 · Seehra et al. · 2012 [cited by applicant]
US 8252900B2 · Knopf et al. · 2012 [cited by applicant]
US 8318135B2 · O'Connor-McCourt et al. · 2012 [cited by applicant]
US 8343933B2 · Knopf et al. · 2013 [cited by applicant]
US 8361957B2 · Seehra et al. · 2013 [cited by applicant]
US 8629109B2 · Knopf et al. · 2014 [cited by applicant]
US 8658135B2 · O'Connor-McCourt et al. · 2014 [cited by applicant]
US 8703927B2 · Seehra et al. · 2014 [cited by applicant]
US 8815247B2 · Govindappa et al. · 2014 [cited by applicant]
US 8895016B2 · Sherman et al. · 2014 [cited by applicant]
US 9138459B2 · Knopf et al. · 2015 [cited by applicant]
US 9163075B2 · Knopf et al. · 2015 [cited by applicant]
US 9399669B2 · Knopf et al. · 2016 [cited by applicant]
US 9439945B2 · Seehra et al. · 2016 [cited by applicant]
US 9932379B2 · Seehra et al. · 2018 [cited by applicant]
US 10131700B2 · Seehra et al. · 2018 [cited by applicant]
US 10259861B2 · Knopf et al. · 2019 [cited by applicant]
US 10550170B2 · Sherman et al. · 2020 [cited by applicant]
US 10689427B2 · Seehra et al. · 2020 [cited by applicant]
US 10829532B2 · Seehra et al. · 2020 [cited by applicant]
US 10913782B2 · Han et al. · 2021 [cited by applicant]
US 11524990B2 · Sherman et al. · 2022 [cited by applicant]
US 11945856B2 · O'Connor-McCourt et al. · 2024 [cited by applicant]
US 20050203022A1 · Gotwals et al. · 2005 [cited by applicant]
US 20070244042A1 · Sun et al. · 2007 [cited by applicant]
US 20150056199A1 · Kumar et al. · 2015 [cited by applicant]
US 20150225483A1 · Lo · 2015 [cited by applicant]
US 20170291935A1 · Sherman et al. · 2017 [cited by applicant]
US 20180148491A1 · Han et al. · 2018 [cited by applicant]
US 20200055919A1 · Kumar et al. · 2020 [cited by applicant]
US 20200071383A1 · Sherman et al. · 2020 [cited by applicant]
US 20200407415A1 · Seehra et al. · 2020 [cited by applicant]
US 20220306724A1 · Kumar et al. · 2022 [cited by applicant]
US 20230079602A1 · Seehra et al. · 2023 [cited by applicant]
US 20230087128A1 · Seehra et al. · 2023 [cited by applicant]
US 20230129812A1 · Kumar · 2023 [cited by applicant]
US 20230183319A1 · Kumar et al. · 2023 [cited by applicant]
US 20230287084A1 · O'Connor-McCourt et al. · 2023 [cited by applicant]
EP 3523328A1 · 2019 [cited by applicant]
EP 3737406A1 · 2020 [cited by applicant]
EP 4100430A1 · 2022 [cited by applicant]
EP 4100431A1 · 2022 [cited by applicant]
EP 4121078A1 · 2023 [cited by applicant]
EP 4121088A1 · 2023 [cited by applicant]
EP 4221736A1 · 2023 [cited by applicant]
EP 4274600A1 · 2023 [cited by applicant]
WO WO9954440A1 · 1999 [cited by applicant]
WO WO0183525A2 · 2001 [cited by applicant]
WO WO2005028517A2 · 2005 [cited by applicant]
WO WO2008113185A1 · 2008 [cited by applicant]
WO WO2008157367A1 · 2008 [cited by applicant]
WO WO2010031168A1 · 2010 [cited by applicant]
WO WO2010099219A2 · 2010 [cited by applicant]
WO WO2012071649A1 · 2012 [cited by applicant]
WO WO2012142515A2 · 2012 [cited by applicant]
WO WO2013000234A1 · 2013 [cited by applicant]
WO WO2017037634A1 · 2017 [cited by applicant]
WO WO2017091706A1 · 2017 [cited by applicant]
WO WO2018067874A1 · 2018 [cited by applicant]
WO WO2018158727A1 · 2018 [cited by applicant]
WO WO2019140283A1 · 2019 [cited by applicant]
WO WO2021158675A1 · 2021 [cited by applicant]
WO WO2021158695A1 · 2021 [cited by applicant]
WO WO2021189010A1 · 2021 [cited by applicant]
WO WO2021189019A1 · 2021 [cited by applicant]
WO WO2022072882A1 · 2022 [cited by applicant]
WO WO2022150590A1 · 2022 [cited by applicant]
WO WO2022271571A1 · 2022 [cited by applicant]
WO WO2022271716A2 · 2022 [cited by applicant]
WO WO2023022968A2 · 2023 [cited by applicant]
WO WO2023023345A2 · 2023 [cited by applicant]
WO WO2023108137A1 · 2023 [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/CA2023/050116 dated Jul. 30, 2024, 10 pages. [cited by applicant]
Abdulkadyrov et al., “Sotatercept in patients with osteolytic lesions of multiple myeloma”, Br J Haematol. Jun. 2014; 165(6): 814-823. Epub Mar. 21, 2014. [cited by applicant]
Akpan et al., “The effects of a Soluble Activin Type IIB Receptor on Obesity and Insulin Sensitivity”, International Journal of Obesity, Nov. 2009; 33(11): 1265-1273. [cited by applicant]
Amato et al., “Treatment of Sporadic Inclusion Body Myositis with Bimagrumab”, American Academy of Neurology, Dec. 9, 2014; 83(24): 2239-2246. [cited by applicant]
Attie et al., “A Phase 1 Study of ACE-536, a Regulator of Erythroid Differentiation, in Healthy Volunteers”, Am J Hematol. Jul. 2014; 89(7): 766-770. [cited by applicant]
Attie et al., “A Single Ascending-Dose Study of Muscle Regulator ACE-031 in Healthy Volunteers”, Muscle & Nerve, Mar. 2013; 47(3):416-423. [cited by applicant]
Attie et al. “ACE-031 (Soluble Activin Receptor Type IIB-IgG1) Increases Muscle Mass by Inhibiting Myostatin and Other Negative Regulators of Muscle: Non-Clinical and Clinical Studies”, Acceleron Pharma Inc., Endo Meeti… [cited by applicant]
Austin and Lloyd, “Genetics and Mediators in Pulmonary Arterial Hypertension”, Clinics in Chest Medicine Mar. 2007; 28(1): 43-57. [cited by applicant]
[Author Unknown] “Acceleron Presents Preliminary ACE-031 Results from a Phase 1 Multiple Ascending Dose Study in Healthy Volunteers”. Acceleron Pharma (Oct. 13, 2010); Cambridge MA, Pipeline Review. Retrieved from the I… [cited by applicant]
Cadena et al., “Administration of a Soluble Activin Type IIB Receptor Promotes Skeletal Muscle Growth Independent of Fiber Type”, Journal of Applied Physiology, May 2010, vol. 109, No. 3, pp. 635-642. [cited by applicant]
Calvier et al., “LRP1 Deficiency in Vascular SMC Leads To Pulmonary Arterial Hypertension That Is Reversed By PPARγ Activation”, Circ Res. Jun. 7, 2019; 124(12): 1778-1785. Epub Apr. 26, 2019. [cited by applicant]
Campbell et al., “Myostatin Inhibitor ACE-031 Treatment of Ambulatory Boys With Duchenne Muscular Dystrophy: Results of a Randomized, Placebo-Controlled Clinical Trial”, Muscle Nerve. Apr. 2017; 55(4): 458-464. Epub Dec… [cited by applicant]
Cappellini et al., “Sotatercept, a novel transforming growth factor ß ligand trap, improves anemia in ß-thalassemia: a phase II, open-label, dose-finding study”, Haematologica. Mar. 2019; 104(3): 477-484. Epub Oct. 18, … [cited by applicant]
Coyne et al., “Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular Calcification”, Kidney Int Rep. Aug. 13, 2019; 4(11): 1585-1597. eCollection Nov. 2019. [cited by applicant]
Desroches-Castan et al., “BMP9 and BMP10: Two close vascular quiescence partners that stand out”, Dev Dyn. Jan. 2022; 251(1): 158-177. [cited by applicant]
Garito et al., “Effects of Bimagrumab, an Activin Receptor Type II Inhibitor, on Pituitary Neurohormonal Axes”, Clinical Endocrinology(Oxf), Jun. 2018, vol. 88, No. 6, pp. 908-919. [cited by applicant]
Heymsfield et al., “Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults with Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial”, JAMA Network, Open. Jan. 13, 2021, 4;4(1):e2033457, 13 pages. [cited by applicant]
Hoeper et al., “Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension”, New England Journal of Medicine (2023); vol. 388, No. 16, pp. 1478-1490, 13 pages. [cited by applicant]
Hoeper et al., “Supplementary Appendix for Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension”, New England Journal of Medicine (2023); vol. 388, No. 16, 70 pages. [cited by applicant]
Humbert et al., “Sotatercept for the Treatment of Pulmonary Arterial Hypertension”, N Engl J Med. Apr. 1, 2021; 384(13): 1204-1215. [cited by applicant]
Humbert et al., “Sotatercept for the Treatment of Pulmonary Arterial Hypertension: PULSAR Open-Label Extension”, European Respiratory Journal (Jan. 1, 2022); 61(1), 12 pages. [cited by applicant]
Humbert, Marc, “Update in Pulmonary Hypertension 2008”, Am J Respir Crit Care Med. Apr. 15, 2009; 179(8): 650-656. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/CA2023/050116 dated Apr. 5, 2023, 18 pages. [cited by applicant]
Invitation to Pay for International Application No. PCT/CA2023/050116 dated Feb. 15, 2023, 3 pages. [cited by applicant]
Joshi et al., “Combination Therapy with Sotatercept Analog RAP-011 is Superior to Sildenafil Alone in Severe Experimental PAH and RAP-011 Benefits Persist After Treatment Cessation”, Acceleron Pharma, Cambridge, MA, Pos… [cited by applicant]
Joshi et al., “Sotatercept Analog Suppresses Inflammation to Reverse Experimental Pulmonary Arterial Hypertension”, Scientific Reports, May 12, 2022; 12(1):7803, 18 pages. [cited by applicant]
Kanashiro-Takeuchi et al., “Efficacy of a Growth Hormone-Releasing Hormone Agonist in a Murine Model of Cardiometabolic Heart Failure with Preserved Ejection Fraction”, bioRxiv, Sep. 19, 2022; https://www.biorxiv.org/co… [cited by applicant]
Komrokji et al., “Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial”, Lancet Haematol. Feb. 2018; 5(2): e63-e72. Epub … [cited by applicant]
Latres et al., “Activin A more Prominently Regulates Muscle Mass in Primates than Does GDF8”, Nature Communications, Apr. 28, 2017, vol. 8, No. 15153, 13 pages. [cited by applicant]
Li et al., “Elevated Plasma Connective Tissue Growth Factor Levels in Children with Pulmonary Arterial Hypertension Associated with Congenital Heart Disease”, Pediatr Cardiol. Apr. 2016; 37(4): 714-721. Epub Dec. 29, 20… [cited by applicant]
Nagano et al., “Apelin Elevates Blood Pressure in ICR Mice with L-NAME-Induced Endothelial Dysfunction”, Molecular Medicine Reports, May 1, 2013; vol. 7, No. 5, pp. 1371-1375. [cited by applicant]
Ongaro et al., “Myostatin is a Major Endocrine Driver of Follicle-Stimulating Hormone Synthesis”, bioRxiv Sep. 1, 2023, [retrieved on Mar. 8, 2024] at URL: https://www.biorxiv.org/content/10.1101/2023.08.30.555595v1#:˜:… [cited by applicant]
Ordonez et al., “Administration of KER-050, A Novel ACTRIIA Ligand Trap, To Healthy Participants Elicited Robust and Sustained Increases in Hemoglobin and Platelets”, Poster. European Hematology Association. Posted Jun.… [cited by applicant]
Pi et al., “Vascular Endothelial Cell-Specific Connective Tissue Growth Factor (CTGF) Is Necessary for Development of Chronic Hypoxia-Induced Pulmonary Hypertension”, Front Physiol. Feb. 27, 2018; 9: 138, 13 pages. eCol… [cited by applicant]
Quarck and Perros, “Rescuing BMPR2-driven endothelial dysfunction in PAH: a novel treatment strategy for the future?”, Stem Cell Investig. Jun. 14, 2017; 4: 56, 3 pages. eCollection 2017. [cited by applicant]
Raftopoulos et al., “Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic r… [cited by applicant]
Roh et al., “Activin Type II Receptor Signaling in Cardiac Aging and Heart Failure”. Science Translational Medicine, Mar. 6, 2019, vol. 11, No. 482:eaau8680, 31 pages. [cited by applicant]
Ruckle et al., “Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study of ACE-011 (ActRIIA-IgG1) in Postmenopausal Women”, J Bone Miner Res. Apr. 2009; 24(4): 744-752. [cited by applicant]
Ryanto et al., “An endothelial activin A-bone morphogenetic protein receptor type 2 link is overdriven in pulmonary hypertension”, Nature Communications. Mar. 19, 2021; 12(1): 1720, 14 pages. [cited by applicant]
Schang et al., “Abstract 10487: In Vivo Efficacy of HS135, a Novel Activin and GDF Trap for the Treatment of Pulmonary Hypertension (PH) and Metabolic Syndrome (MetS)”, AHA/ASA Journals, Circulation. Oct. 30, 2022; vol.… [cited by applicant]
Schang et al., “HS135, a Best-in-Class Activin and GDF Ligand Trap, is Efficacious in Experimental Left Heart Failure” Poster, Presented at HFSA 2023 by 35Pharma, Montreal, Canada, 1 page. [cited by applicant]
Schang et al., “HS135, A Novel Activin and GDF Trap, Is Efficacious in Experimental Pulmonary Hypertension and Heart Failure”, Control/Tracking No. 23-A-16866-ACC, ACC Abstract, Presented Sep. 28, 2022, 35Pharma Inc.; J… [cited by applicant]
Schang et al., “HS135, A Novel Activin and GDF Trap, Is Efficacious in Experimental Pulmonary Hypertension and Heart Failure”, Presentation by Maureen O'Connor, PhD, 35 Pharma Inc., American College of Cardiology Confer… [cited by applicant]
Schang et al., “HS135, A Novel Activin and GDF Trap, is Efficacious in Models of Pulmonary Hypertension (PH) and Heart Failure (HF)”, Abstract #8622, Poster, American Thoracic Society, presented at ATS 2023, 1 page. [cited by applicant]
Schang et al., “HS135, a Novel Activin and GDF Trap, Is Efficacious in Models of Pulmonary Hypertension (PH) and Heart Failure (HF)”, Control/Tracking No. 2023-S-8622-ATS, ATS Abstract Submission dated Jan. 10, 2023, AT… [cited by applicant]
Schang et al., “HS135, a Novel Activin and GDF Trap is Highly Efficacious in Models of Group 1 and Group 2 Pulmonary Hypertension”. ERS 2023, Abstract # PA450, Poster, 35Pharma, Montreal, Canada 2023, 1 page. [cited by applicant]
Schang et al., “HS135, a Novel Activin and GDF Trap is Highly Efficacious in Models of Group 1 and Group 2 Pulmonary Hypertension”. European Respiratory Journal (Oct. 2023); vol. 62, Issue 67, Abstract, 1 page. [cited by applicant]
Schang et al., “HS135, A Novel Activin and GDF Trap, is Highly Efficacious in Preclinical Models of Pulmonary Hypertension and Obesity-Associated Heart Failure with Preserved Ejection Fraction”. ESC Poster, Aug. 27, 202… [cited by applicant]
Schang et al., “HS135, A Novel Activin and GDF Trap, is Highly Efficacious in Preclinical Models of Pulmonary Hypertension and Obesity-Associated Heart Failure with Preserved Ejection Fraction” European Heart Journal (N… [cited by applicant]
Schang et al., “HS135, a Novel Activin and GDF Trap with Dual Cardiopulmonary and Metabolic Mode of Action, is Efficacious in an Obesogenic Model of Heart Failure”, Control/Tracking No. 2023-A-6662-ENDO, cOASIS ENDO 202… [cited by applicant]
Schang et al., “HS135, a Novel Activin and GDF Trap with Dual Cardiopulmonary and Metabolic Mode of Action, is Efficacious in an Obesogenic Model of Heart Failure”. Poster, Abstract # 6662, ENDO 2023, 35Pharma, Inc., Mo… [cited by applicant]
Schang et al., “HS135: Novel Activin & GDF Ligand Trap for the Treatment of Pulmonary Hypertension (PH)”. Abstract # 35129, Poster # PA4196, Presented at ERS Congress 2022, 35Pharma, Montreal, Canada; 1 page. [cited by applicant]
Schang et al., “HS135: Novel Activin & GDF Ligand Trap for the Treatment of Pulmonary Hypertension (PH)”. European Respiratory Journal, Dec. 2022, vol. 60, Issue 66, 3238, 2 pages, Abstract. [cited by applicant]
Schang et al., “HS135: Novel Activin and GDF Ligand Trap for Treatment of Pulmonary Hypertension (PH)”. Abstract # 4218, Poster # 2073, Presented at CHEST Annual Meeting 2022, 35Pharma, Montreal, Canada, 1 page. [cited by applicant]
Schang et al., “HS135: Novel Activin and GDF Ligand Trap for Treatment of Pulmonary Hypertension (PH)”. Chest Journal, PAH Abstract Posters, Original Investigation Posters, Oct. 18, 2022, vol. 162, Issue 4, Supplement A… [cited by applicant]
Schang et al., “In Vivo Efficacy of HS135, a Novel Activin and GDF Trap for the Treatment of Pulmonary Hypertension (PH) and Metabolic Syndrome (MetS)”, Abstract # 10487, Poster # MO4171, Presented at AHA Scientific Ses… [cited by applicant]
Schiattarella, G.G et al., “Nitrosative stress drives heart failure with preserved ejection fraction,” Nature, vol. 568, Apr. 18, 2019, pp. 351-356, including Methods and Extended Data (28 total pages). [cited by applicant]
Sevilla-Pérez et al., “Shroom expression is attenuated in pulmonary arterial hypertension”, Eur Respir J. Oct. 2008; 32(4): 871-880. Epub Jun. 11, 2008. [cited by applicant]
Sherman et al., “Multiple-Dose, Safety, Pharmacokinetic, and Pharmacodynamic Study of Sotatercept (ActRIIA-IgG1), a Novel Erythropoietic Agent, in Healthy Postmenopausal Women”, J Clin Pharmacol. Nov. 2013; 53(11): 1121… [cited by applicant]
Tam et al., “Selective deletion of connective tissue growth factor attenuates experimentally-induced pulmonary fibrosis and pulmonary arterial hypertension”, Int J Biochem Cell Biol. May 2021; 134: 105961, 12 pages. Epu… [cited by applicant]
Tao et al., “First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors”, Clinical Cancer Research, May 2019, vol. 25, No. 18, pp. 54… [cited by applicant]
Vanhoutte et al., “Pharmacokinetics and Pharmacodynamics of Garetosmab (Anti-Activin A): Results From a First-in-Human Phase 1 Study”, The Journal of Clinical Pharmacology, Jun. 2020, vol. 60, No. 11, pp. 1424-1431. [cited by applicant]
Yung et al., “ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension”, Sci Transl Med. May 13, 2020; 12(543): eaaz5660, 13 pages. [cited by applicant]